Insider Selling: Equillium, Inc. (NASDAQ:EQ) COO Sells $18,750.00 in Stock

Equillium, Inc. (NASDAQ:EQ) COO Christine Zedelmayer sold 15,000 shares of the business’s stock in a transaction dated Monday, October 28th. The shares were sold at an average price of $1.25, for a total transaction of $18,750.00. Following the transaction, the chief operating officer now directly owns 135,246 shares in the company, valued at approximately $169,057.50. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Equillium Trading Down 3.6 %

Equillium stock opened at $0.83 on Friday. Equillium, Inc. has a 12-month low of $0.45 and a 12-month high of $3.25. The stock has a market cap of $29.40 million, a P/E ratio of -3.32 and a beta of 1.83. The company has a fifty day simple moving average of $0.96 and a 200-day simple moving average of $1.04.

Equillium (NASDAQ:EQ) last issued its quarterly earnings data on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.16. Equillium had a negative return on equity of 36.88% and a negative net margin of 19.51%. The company had revenue of $13.85 million during the quarter, compared to analysts’ expectations of $8.15 million. As a group, sell-side analysts forecast that Equillium, Inc. will post -0.14 earnings per share for the current fiscal year.

Institutional Trading of Equillium

A hedge fund recently raised its stake in Equillium stock. Renaissance Technologies LLC increased its stake in Equillium, Inc. (NASDAQ:EQ) by 43.6% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 300,400 shares of the company’s stock after acquiring an additional 91,200 shares during the period. Renaissance Technologies LLC owned approximately 0.85% of Equillium worth $208,000 as of its most recent SEC filing. 27.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 price objective on shares of Equillium in a report on Monday, August 19th.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.